[{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"9ae6d61c-52ac-447d-9656-ee355853d0dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04068194","created_at":"2023-11-15T17:14:49.418Z","updated_at":"2025-02-25T13:52:57.960Z","phase":"Phase 1/2","brief_title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","source_id_and_acronym":"NCT04068194","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"f9665a10-dce3-43c7-a423-8c44b5bd6d32","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944941","created_at":"2021-01-18T19:25:25.225Z","updated_at":"2025-02-25T14:15:21.839Z","phase":"Phase 2","brief_title":"Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer","source_id_and_acronym":"NCT03944941","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-18"},{"id":"442d5c06-75a4-48d9-85ea-9b9fc557a2ef","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT03252938","created_at":"2021-01-17T17:46:57.179Z","updated_at":"2025-02-25T15:10:38.137Z","phase":"Phase 1","brief_title":"Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors","source_id_and_acronym":"NCT03252938 - INSIGHT","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 08/15/2017","start_date":" 08/15/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-13"},{"id":"b45ee881-2449-41ad-a03b-5247e63186d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03719768","created_at":"2021-01-18T18:13:52.602Z","updated_at":"2025-02-25T15:17:55.867Z","phase":"Phase 1","brief_title":"Avelumab With Radiotherapy in Patients With Leptomeningeal Disease","source_id_and_acronym":"NCT03719768","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/10/2019","start_date":" 06/10/2019","primary_txt":" Primary completion: 07/19/2022","primary_completion_date":" 07/19/2022","study_txt":" Completion: 08/21/2024","study_completion_date":" 08/21/2024","last_update_posted":"2025-02-12"},{"id":"065ef196-20b8-4fd5-a099-c2330533ea52","acronym":"SELECTIO-UC","url":"https://clinicaltrials.gov/study/NCT06820255","created_at":"2025-02-25T15:31:16.755Z","updated_at":"2025-02-25T15:31:16.755Z","phase":"Phase 4","brief_title":"DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","source_id_and_acronym":"NCT06820255 - SELECTIO-UC","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" HER-2 • PD-L1 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 01/07/2025","start_date":" 01/07/2025","primary_txt":" Primary completion: 01/07/2026","primary_completion_date":" 01/07/2026","study_txt":" Completion: 01/07/2027","study_completion_date":" 01/07/2027","last_update_posted":"2025-02-11"},{"id":"7f1ad480-25c7-4c95-b0bc-1138e8d8a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT03076554","created_at":"2021-01-18T15:09:28.588Z","updated_at":"2025-02-25T16:51:49.925Z","phase":"Phase 2","brief_title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","source_id_and_acronym":"NCT03076554","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/19/2017","start_date":" 04/19/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-04"},{"id":"92ca3540-a2c4-478b-a664-5f10aca9b49c","acronym":"MAIN-CAV","url":"https://clinicaltrials.gov/study/NCT05092958","created_at":"2021-10-26T21:53:06.212Z","updated_at":"2025-02-25T16:53:55.916Z","phase":"Phase 3","brief_title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","source_id_and_acronym":"NCT05092958 - MAIN-CAV","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 654","initiation":"Initiation: 06/03/2022","start_date":" 06/03/2022","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2025-02-04"},{"id":"8aeac3d2-4546-44a5-acba-91be57ffcaba","acronym":"JAVELIN Lung 100","url":"https://clinicaltrials.gov/study/NCT02576574","created_at":"2021-01-18T12:29:38.026Z","updated_at":"2025-02-25T16:15:12.851Z","phase":"Phase 3","brief_title":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","source_id_and_acronym":"NCT02576574 - JAVELIN Lung 100","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • paclitaxel • Bavencio (avelumab) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 1214","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/06/2021","primary_completion_date":" 12/06/2021","study_txt":" Completion: 01/29/2024","study_completion_date":" 01/29/2024","last_update_posted":"2025-01-31"},{"id":"412de90b-4e3b-4146-9e47-4f34d9a4603a","acronym":"QUILT-3.055","url":"https://clinicaltrials.gov/study/NCT03228667","created_at":"2021-01-18T15:56:08.764Z","updated_at":"2025-02-25T17:35:53.589Z","phase":"Phase 2","brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03228667 - QUILT-3.055","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" BRAF • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type","tags":["BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/11/2018","start_date":" 12/11/2018","primary_txt":" Primary completion: 08/31/2029","primary_completion_date":" 08/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"93bcdd9b-070c-4fdf-823a-5fbeb9dce128","acronym":"NET-002","url":"https://clinicaltrials.gov/study/NCT03278379","created_at":"2021-01-18T16:11:20.999Z","updated_at":"2025-02-25T16:06:53.173Z","phase":"Phase 2","brief_title":"Avelumab in G2-3 NET","source_id_and_acronym":"NCT03278379 - NET-002","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" PD-L1 • TMB","pipe":"","alterations":" ","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 07/26/2021","primary_completion_date":" 07/26/2021","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2024-12-24"},{"id":"a823c207-e7e1-4f29-8a31-680d49989ddd","acronym":"AVIATOR","url":"https://clinicaltrials.gov/study/NCT03414658","created_at":"2021-01-18T16:50:49.598Z","updated_at":"2025-02-25T13:52:30.920Z","phase":"Phase 2","brief_title":"The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab \u0026 Utomilumab in Advanced HER2+ Breast Cancer","source_id_and_acronym":"NCT03414658 - AVIATOR","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Bavencio (avelumab) • vinorelbine tartrate • utomilumab (PF-05082566)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-11-06"},{"id":"71a001f3-5897-407f-9e6e-a8db93f82ce5","acronym":"AvR-CHOP","url":"https://clinicaltrials.gov/study/NCT03244176","created_at":"2021-01-18T16:01:39.305Z","updated_at":"2025-02-25T16:06:39.998Z","phase":"Phase 1","brief_title":"Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study","source_id_and_acronym":"NCT03244176 - AvR-CHOP","lead_sponsor":"Austin Health","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Bavencio (avelumab) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/21/2017","start_date":" 07/21/2017","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-07-30"},{"id":"88834346-c6d3-46c6-ab88-e163b86f1000","acronym":"UNSCARRed","url":"https://clinicaltrials.gov/study/NCT03737721","created_at":"2024-06-15T04:01:20.965Z","updated_at":"2024-07-02T16:34:25.725Z","phase":"Phase 2","brief_title":"The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy","source_id_and_acronym":"NCT03737721 - UNSCARRed","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/12/2019","start_date":" 04/12/2019","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 12/08/2024","study_completion_date":" 12/08/2024","last_update_posted":"2024-06-14"},{"id":"0c02cc4f-da25-44d0-b391-3f1638d91362","acronym":"AMPLIFY-NEOVAC","url":"https://clinicaltrials.gov/study/NCT03893903","created_at":"2021-01-18T19:10:49.432Z","updated_at":"2024-07-02T16:34:38.157Z","phase":"Phase 1","brief_title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","source_id_and_acronym":"NCT03893903 - AMPLIFY-NEOVAC","lead_sponsor":"German Cancer Research Center","biomarkers":" ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • IDH1R132H peptide vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/19/2018","start_date":" 10/19/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-05"},{"id":"b28a300d-a648-41cb-b9b3-e37a6c33dd25","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04173507","created_at":"2021-01-18T20:21:36.422Z","updated_at":"2024-07-02T16:34:59.352Z","phase":"Phase 2","brief_title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04173507 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 11/24/2021","primary_completion_date":" 11/24/2021","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"7d24d9e1-4dcb-42b7-a602-4f6bcfc0236d","acronym":"InCITe","url":"https://clinicaltrials.gov/study/NCT03971409","created_at":"2021-01-18T19:32:12.157Z","updated_at":"2024-07-02T16:35:04.267Z","phase":"Phase 2","brief_title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","source_id_and_acronym":"NCT03971409 - InCITe","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-13"},{"id":"a3950726-a4fc-4f10-89c7-7699eae995e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04954599","created_at":"2021-07-08T14:52:43.900Z","updated_at":"2024-07-02T16:35:08.431Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","source_id_and_acronym":"NCT04954599","lead_sponsor":"Maastricht University Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-04-22"},{"id":"c67606ea-7796-46a1-9d35-f3d0edacc3ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912572","created_at":"2021-01-18T14:17:54.432Z","updated_at":"2024-07-02T16:35:08.730Z","phase":"Phase 2","brief_title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02912572","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation • MSH6 expression","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-19"},{"id":"ffcba248-e63f-4a6d-8229-27993beda570","acronym":"I-MAT","url":"https://clinicaltrials.gov/study/NCT04291885","created_at":"2023-11-22T20:15:59.147Z","updated_at":"2024-07-02T16:35:09.734Z","phase":"Phase 2","brief_title":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","source_id_and_acronym":"NCT04291885 - I-MAT","lead_sponsor":"Melanoma and Skin Cancer Trials Limited","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-15"},{"id":"07e46b79-8fde-4376-b4a4-3d01c1ae210f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03558139","created_at":"2021-01-18T17:30:51.613Z","updated_at":"2025-02-25T16:07:59.888Z","phase":"Phase 1","brief_title":"Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy","source_id_and_acronym":"NCT03558139","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • magrolimab (ONO-7913)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 12/03/2020","primary_completion_date":" 12/03/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2024-04-01"}]